STOCK TITAN

Therapeutic Solutions International Inc - TSOI STOCK NEWS

Welcome to our dedicated news page for Therapeutic Solutions International (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions International.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Therapeutic Solutions International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Therapeutic Solutions International's position in the market.

Rhea-AI Summary
Therapeutic Solutions International subsidiary recruits renowned medical doctor for breast cancer immunotherapy research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) files patent for manufacturing neutrophils that can stop unwanted immune responses while allowing the body to fight bacteria and viruses. Neutrophils generated with IL-10 can block rejection responses and allow for transplantation of therapeutic cells. This could change the biotech industry's approach to immune responses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International appoints Dr. Navneet Boddu to its Scientific Advisory Board, plans to expand patient access to JadiCells
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Therapeutic Solutions International announces potential breakthrough in cancer immunotherapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International develops new therapeutic approach for treatment of Frontotemporal Dementia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Res Nova Bio reports findings supporting clinical translation of Pterostilbene-Abortion Pill Cancer Adjuvant. Synergistic suppression of breast cancer growth shown when used with anti-PD1 and anti-CTLA4 antibodies. FloraStilbene™ increases efficacy of standard chemotherapies. Patent application filed. Positive development for non-toxic immunotherapies of breast cancer. Manufacturing and distribution partner secured. Hope for patients with limited options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Therapeutic Solutions International (TSOI) has achieved a significant production milestone by successfully generating a quality control tested Master Cell Bank of its JadiCell universal donor stem cell product. This allows the company to conduct a Phase III clinical trial with cells possessing FDA-approved characteristics. Previously, the JadiCells demonstrated a 100% reduction in lethality in COVID-19 patients under 85 years old in a Phase I/II clinical trial. The manufacturing of JadiCells in-house by Allogen Biologics will increase the number of patients that can be treated and generate more data in a shorter time period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary
Therapeutic Solutions International (TSOI) has received a Notice of Allowance from the US Patent and Trademark Office for its patent application on a novel composition of matter for preventing suicide. The company's approach focuses on identifying patients at risk of suicide using immunology-based assays. The patent grant is a significant milestone for the company as it works towards a world without suicide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Therapeutic Solutions International's subsidiary, Res Nova Bio, has filed a patent for its immunotherapy-enhancing product, FloraStilbene™. The product has been shown to suppress the loss of T cell activity caused by growing breast cancer by stopping the degradation of a protein called T cell receptor zeta chain. The company plans to initiate a Phase I/II clinical trial in advanced breast cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
Rhea-AI Summary
Therapeutic Solutions International, Inc. (TSOI) has announced new data and filing with the FDA for Orphan Drug Designation of its JadiCell adult stem cell in the treatment of Frontotemporal Dementia, a neurodegenerative disease that is the leading cause of dementia in patients under 60 years old. No therapies have been shown to reduce its progression. The JadiCell cell therapy product has previously been successful in treating patients with chronic traumatic encephalopathy (CTE) and recent data suggests the possibility of utilizing these cells in Frontotemporal Dementia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Therapeutic Solutions International Inc

OTC:TSOI

TSOI Rankings

TSOI Stock Data

2.89M
2.90B
20.03%
Tobacco Manufacturing
Manufacturing
Link
United States
Elk City